These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8526027)

  • 21. Induction of IgA and IgG antibodies in vaginal fluid, serum and saliva following immunization of genital and gut associated lymphoid tissue.
    Bergmeier LA; Tao L; Gearing AJ; Adams S; Lehner T
    Adv Exp Med Biol; 1995; 371B():1567-73. PubMed ID: 7502858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mucosal administration of completely non-replicative vaccinia virus recombinant Dairen I strain elicits effective mucosal and systemic immunity.
    Yoshino N; Kanekiyo M; Hagiwara Y; Okamura T; Someya K; Matsuo K; Ami Y; Sato S; Yamamoto N; Honda M
    Scand J Immunol; 2008 Nov; 68(5):476-83. PubMed ID: 18803609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral administration of cholera toxin-Sendai virus conjugate potentiates gut and respiratory immunity against Sendai virus.
    Liang XP; Lamm ME; Nedrud JG
    J Immunol; 1988 Sep; 141(5):1495-501. PubMed ID: 2842395
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of the B subunit of cholera toxin in potentiating immune responses to the recombinant hemagglutinin/adhesin domain of the gingipain Kgp from Porphyromonas gingivalis.
    Zhang P; Yang QB; Balkovetz DF; Lewis JP; Clements JD; Michalek SM; Katz J
    Vaccine; 2005 Sep; 23(39):4734-44. PubMed ID: 15955601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancement of anti-Shigella lipopolysaccharide (LPS) response by addition of the cholera toxin B subunit to oral and intranasal proteosome-Shigella flexneri 2a LPS vaccines.
    Orr N; Arnon R; Rubin G; Cohen D; Bercovier H; Lowell GH
    Infect Immun; 1994 Nov; 62(11):5198-200. PubMed ID: 7927807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env, and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes.
    Lagranderie M; Winter N; Balazuc AM; Gicquel B; Gheorghiu M
    AIDS Res Hum Retroviruses; 1998 Dec; 14(18):1625-33. PubMed ID: 9870315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral immunization of mice with a glycoconjugate vaccine containing the O157 antigen of Escherichia coli O157:H7 admixed with cholera toxin fails to elicit protection against subsequent colonization by the pathogen.
    Conlan JW; KuoLee R; Webb A; Cox AD; Perry MB
    Can J Microbiol; 2000 Mar; 46(3):283-90. PubMed ID: 10749542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates.
    Bertley FM; Kozlowski PA; Wang SW; Chappelle J; Patel J; Sonuyi O; Mazzara G; Montefiori D; Carville A; Mansfield KG; Aldovini A
    J Immunol; 2004 Mar; 172(6):3745-57. PubMed ID: 15004179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reproducing SIVΔnef vaccine correlates of protection: trimeric gp41 antibody concentrated at mucosal front lines.
    Voss JE; Macauley MS; Rogers KA; Villinger F; Duan L; Shang L; Fink EA; Andrabi R; Colantonio AD; Robinson JE; Johnson RP; Burton DR; Haase AT
    AIDS; 2016 Oct; 30(16):2427-2438. PubMed ID: 27428745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mucosal priming alters pathogenesis of Rift Valley fever.
    Anderson AO; Snyder LF; Pitt ML; Wood OL
    Adv Exp Med Biol; 1988; 237():717-23. PubMed ID: 3254072
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo.
    Stahl-Hennig C; Coulibaly C; Petry H; Voss G; Dittmer U; Bodemer W; Makoschey B; Jurkiewicz E; Lüke W; Hunsmann G
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S27-32. PubMed ID: 7865316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of the expression and immunogenicity of poliovirus replicons that encode simian immunodeficiency virus SIVmac239 Gag or envelope SU proteins.
    Anderson MJ; Porter DC; Moldoveanu Z; Fletcher TM; McPherson S; Morrow CD
    AIDS Res Hum Retroviruses; 1997 Jan; 13(1):53-62. PubMed ID: 8989427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces Th1/Th2 help for virus-specific immune responses in reproductive tissues.
    Imaoka K; Miller CJ; Kubota M; McChesney MB; Lohman B; Yamamoto M; Fujihashi K; Someya K; Honda M; McGhee JR; Kiyono H
    J Immunol; 1998 Dec; 161(11):5952-8. PubMed ID: 9834076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody response in mice immunized by mucosal routes with formalin-inactivated enteropathogenic Escherichia coli (EPEC) strains.
    Drago-Serrano ME; Manjarréz Hernandez HA; Gavilanes Parra S; Sainz Espuñes Tdel R
    Rev Latinoam Microbiol; 2004; 46(1-2):17-23. PubMed ID: 17061522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Membrane-anchored CCL20 augments HIV Env-specific mucosal immune responses.
    Sun X; Zhang H; Xu S; Shi L; Dong J; Gao D; Chen Y; Feng H
    Virol J; 2017 Aug; 14(1):163. PubMed ID: 28830557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Humoral, mucosal, and cellular immune response to topical immunization with a subunit respiratory syncytial virus vaccine.
    Walsh EE
    J Infect Dis; 1994 Aug; 170(2):345-50. PubMed ID: 8035021
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.
    Zhao J; Pinczewski J; Gómez-Román VR; Venzon D; Kalyanaraman VS; Markham PD; Aldrich K; Moake M; Montefiori DC; Lou Y; Pavlakis GN; Robert-Guroff M
    J Virol; 2003 Aug; 77(15):8354-65. PubMed ID: 12857905
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.
    Pal R; Venzon D; Letvin NL; Santra S; Montefiori DC; Miller NR; Tryniszewska E; Lewis MG; VanCott TC; Hirsch V; Woodward R; Gibson A; Grace M; Dobratz E; Markham PD; Hel Z; Nacsa J; Klein M; Tartaglia J; Franchini G
    J Virol; 2002 Jan; 76(1):292-302. PubMed ID: 11739694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunisation of macaques with SIV env recombinants: specificity of T cell and antibody responses and evaluation of protective efficacy.
    Mills KH; Page M; Kitchin P; Chan L; Jones W; Silvera P; Corcoran T; Flanagan B; Ling C; Thiriart C
    J Med Primatol; 1993; 22(2-3):104-9. PubMed ID: 8411102
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge.
    Glenn GM; Scharton-Kersten T; Vassell R; Mallett CP; Hale TL; Alving CR
    J Immunol; 1998 Oct; 161(7):3211-4. PubMed ID: 9759833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.